STOCKS TELEGRAPH

Tag: Nasdaq

  • Universe Pharmaceuticals (UPC) stock is rising today: Things you need to know

    Universe Pharmaceuticals (UPC) stock is rising today: Things you need to know

    Shares of Universe Pharmaceuticals (UPC) stock were rising today in response to the announcement of the full exercise of Underwriter’s over-allotment option by Univest Securities, LLC for its client Pharmaceuticals INC. UPC stock price saw a push of 28.68% to reach $5.16 a share at the time of this writing. At the previous trading session, UPC stock was red and closed with an 8.24% drop. Let’s deep dive to explore more of it.

    What’s happening?

    Today’s news about the UPC stock explains that Univest Securities, LLC has exercised in full of its Underwriter’s over-allotment option to purchase 750,000  additional shares of its common stock for its client Universe Pharmaceuticals INC. The public offering price for this offering was $5.00 per share and it resulted in the additional gross proceeds worth $3.75 million. Now the total number of sold shares of UPC stock in this offering reached  5.75 million and gross proceeds surged to $28.75 million. Back on March  26, 2021,  Univest closed the initial public offering for its client Universe Pharmaceuticals of 5 million shares of its common stock which was previously announced on March 23, 2021.

    Use of Proceeds:

    UPC stock has the plan to use proceeds from this offering in the advancement of manufacturing facilities as well as for research and development purposes. Part of these proceeds will be used for marketing, branding, general and other cooperate purposes.

    About UPC stock:

    Universe Pharmaceuticals INC (UPC), a subsidiary of Sununion Holding Group Limited, is the manufacturer, marketer, distributor, and seller of traditional Chinese medicine products in the Republic of China.UPC’s core focus is to cure elders suffering from various chronic diseases. Furthermore, UPC  is also the seller of third-party producer’s products including biomedical drugs, medical instruments as well as traditional Chinese medicine products.UPC was founded in 2019 and is in Jiangxi, China.

    Conclusion

    Investors are responding to the news announced by the UPC stock, but no one knows how long this trend will continue. Proceeds from the offering will help Universe Pharmaceutical in its various operational as well as marketing areas. In a nutshell, investors having long-term prospects need to do analyze UPC fundamentals, balance sheet, and development prospects before adding them to their portfolio.

  • Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Shares of Savara Inc. (SVRA) continued to gain in Wednesday’s pre-market trading session. SVRA stock price saw an uptrend of 7.46% to reach $2.09 a share as of this writing. Savara stock was up by 21.56% at the previous closing. It seems that analyst rating is driving the SVRA stock price to high. Let’s understand the bullish sentiment in depth.

    Analyst Review on SVRA stock.

    Savara Inc. (SVRA) is working as an orphan disease lung company mainly focused on autoimmune pulmonary alveolar proteinosis (aPAP), a disease in which excessive protein in the lungs causes difficulty in breathing.

    Savara was performing well in the previous trading session and continuing the trend so far. Some of the street members believe that the current share price of SVRA stock points to the effective entry point. A famous piper sandler analyst Yasmeen Rahimi has given the buy rating to SVRA stock and set a $7 target price which suggests that SVRA stock has the potential to soar over 309% in the coming year.

    Rahimi thinks that Molgradexhas the great potential to treat autoimmune pulmonary alveolar proteinosis (PAP) and would be proved to be game-changer therapeutic in the future. Hence there is a strong possibility that SVRA stock would outperform in the future. The analyst further depicted the validation of Molgradex by saying that it has already received the Orphan Drug Designation in the U.S for seven years and EU for ten years in addition to Fast Track Designation and Breakthrough Therapy Designation by FDA.

    Previous Event

    Savara stock announced the public offering of shares of its common stock on March 10, 2021, which SVRA closed on March 15, 2021. A total of  57,479,978 shares were included in that offering at $1.45 per share. The net proceeds resulted from this offering were intended to support the working capital of Savara’s operations in different sectors.

    Conclusion:

    Savara stock is rising as investors are responding in response to the analyst rating. The three recent reviews of Buy with an average target price of $4.67 point to the 173% growth for this penny stock in the next year. Hence SVRA stock can be a good bet in long run.

  • Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) received the approval of Fast Track Designation for Annamycin by the FDA after which the MBRX stock happened to be green today. MBRX stock price saw an uptrend of 21.08% to reach $4.48 a share as of this writing. The MBRX stock was down with a 3.39 drop at the previous closing. Let’s have a look at current scenarios.

    A Brief look at Approval:

    Moleculin Biotech is mainly working on the treatment of tumors and viruses via the development of oncology drug products. Moleculin stock recently announced that it has got approval for fast-track designation for Annamycin, an anthracycline antibiotic, by the U.S. Food and Drug Administration. In connection with this approval, MBRX will now be able to review Annamycin results against the treatment of soft tissue sarcoma (STS) lung metastases. There are good chances for Moleculin to approve its product against STS lung metastases as well as acute myeloid leukemia.

    Why Annamycin is better?

    Approximately 130000 cases of Soft tissue sarcomas are reported annually around the globe and most of them are handled through the surgical procedure. Analysis shows that 20 to 50% of these cases metastasize to the lungs and once it happens, it then becomes more difficult to treat such cases. So far treatment is very limited for this condition due to severe cardiotoxicity effects by previously approved drugs. Annamycin on the other hand proved to be much effective so far as it does not cause severe cardiotoxicity in patients and hence better than the former drugs.

    Financial View  of MBRX stock

    Recently announced earnings results of RMBX stock show that Moleculin research and development surged to $12.8 million in 2020 as compared to $11.0 million in 2019 due to increased clinical trials that increased the operational costs. General and administrative costs were recorded at $6.8 million in 2020 while these were $6.3 million in 2019. An increase in these costs is mainly due to an increase in the staff but thanks to the COVID-19 that overall travel expenses were significantly reduced.

    Conclusion:

    MBRX stock is enjoying the bullish sentiment in the stock market in response to fast-track designation approval for Annamycin. Management is optimistic to receive early approval for its product in the future. Hence investors should do fundamental as well as technical analysis of MBRX stock before taking any decision.

  • SRAX stock gains in Pre-Market: Let’s find out why

    SRAX stock announced its fourth quarter and full-year 2020 results after which the SRAX stock saw a boom of 17.39% to reach $5.40 a share in today’s pre-market at the time of this writing. SRAX stock also gained in the previous trading session and was up by 8.49% at closing. Let’s have a look at the financial results.

    Fourth-Quarter Results:

    SRAX stock marked $4.5 million revenue in the fourth quarter of 2020 which represents a whopping increase of 316% as compared to the same period in the previous year and a 74%  increase in comparison to the third quarter of 2020. Gross margin represents the growth of 73% while it was 44% in the same tenure of the prior year. Operating expenses were also increased in the fourth quarter to $5.3 million from $4.8 million in the fourth quarter of 2019.SRAX recorded a net income of $200K in the last three months of 2020 while it suffered a net loss of $4.4 million in the same period of last year.

    Fiscal Year 2020 Results:

    Revenue of SRAX stock reached $8.7M million in 2020 representing a surge of 141% over the year. Gross margins were moved from 53% in the prior year to 70% in 2020.$17.7 million Operating expenses were recorded in 2020 which represents a decrease of $2.1 million or 11%as compared to operating expenses of 2019.EBITDA in 2020 was -$8.4 million while it was -$15.5 million in 2019.Net income of SRAX for 2020 was -$14.7 million while it was -$16.9 in 2019.

    Financial Guidance of SRAX stock:

    SRAX projected its revenue for the fiscal year 2021 in the range of $23M – $25M while $7 million revenue for the second quarter of 2021 is estimated. Sequire, the SaaS platform of SRAX, has been gaining much popularity over time as 183 public companies bought its subscription of it. The subscription rate increased by 92% since SRAX released its third-quarter income of 2020.$16.5 million revenue of Sequire from the existing contracts in 2021 is recorded so far.

    In a Nutshell:

    SRAX stock has been hot among investors after the release of its positive financial results. SRAX Inc has shown significant progress over the year and it seems that momentum is already created for SRAX. Management is deeply focused on meeting the customer demand and adoption of new technologies. Hence SRAX stock can be a good bet for investors in the future.

  • Humanigen, Inc. (HGEN) stock Continues to Gain today: Things you Need to Know

    Humanigen, Inc. (HGEN) stock Continues to Gain today: Things you Need to Know

    Humanigen, Inc. (HGEN) announced positive phase 3 Topline results of lenzilumab,  humanized monoclonal antibody, after which the HGEN stock price saw a surge of 45.42% today’s session to reach $20.34 a share as of this writing. HGEN stock was also green in the previous trading session and at closing, it was up by 1.67% with a $13.99 per share price. Let’s understand more about today’s HGEN news.

    A deep look at Clinical Results.

    Humanigen was performing a phase three clinical trial of lenzilumab for the past couple of months. The study was based on the evaluation of efficacy and safety results of lenzilumab in the hospitalized patients suffering from COVID-19. According to the phase three results, the patients who had received lenzilumab along with steroids or remdesivir were more likely to survive without the use of invasive mechanical ventilation (IMV) as compared to the patients who did not receive the lenzilumab.HGEN was happy to see these results.

    Mayo Clinic was the part of this study and Zelalem Temesgen, MD, who is a professor at Mayo Clinic, was serving as the Principal investigator of this trial. According to him,  lenzilumab proved to be much effective in its results as it significantly reduced the chances of one’s going on a ventilator. Andrew Badley, MD, a professor of Infectious Diseases, showed much excitement about these results. He said that lenzilumab would be an important part of Mayo Clinic in future trials if it gets approval from U.S. Food and Drug Administration.

    Next Goal of Humanigen, Inc.

    After getting exceptional results in phase three clinical trial of lenzilumab, Humanigen’s management is planning to apply for the grant of getting Emergency Use Authorization(EUA)   by the Food and Drug Administration.  Humanigen also sharing these results with different governmental agencies of the U.S as well as authorities of many countries in the globe.

    Financial View of HGEN stock

    On March 10, 2021, Humanigen stock announced its fourth quarter and fiscal year 2020 results according to which HGEN stock recorded the net loss of $89.5 million or $2.42 per share in 2020 as compared to a net loss of $10.3 million or $0.46 per share in 2019. This increase was mainly due to a massive increase in the research and development expenses in 2020. The R&D expenses for 2020 were $72.7 million while these were just $2.6 million in 2019. $67.7 million of cash and cash equivalents were recorded at the end of 2020.

    Conclusion:

    Considering the market sentiment, HGEN stock is in a good position as investors are responding to the news announced by Humanigen, Inc.Positive results of the phase three study would prove to be fruitful for the HGEN stock in the future. Recent earnings report shows that Humanigen has progressed over the year. Hence HGEN stock can be a good bet in the long run.

  • Why Universe Pharmaceuticals Inc (UPC) stock rallied in Pre-Market today?

    Why Universe Pharmaceuticals Inc (UPC) stock rallied in Pre-Market today?

    Shares of Universe Pharmaceuticals Inc (UPC) were soaring in Monday’s pre-market trading session. UPC stock price saw a boom of 83.54% in today’s pre-market to reach $7.47 a share as of this writing. The previous closing price of UPC stock was $4.07 representing a 0.49% gain. Let’s try to figure out the reason behind this bull.

    What’s happening?

    We find no news in today’s date by the UPC stock, no earnings report or analyst upgrades to justify this bull however on March 26, 2021, Univest Securities, LLC did announce the closure of an initial public offering (IPO) for its client Universe Pharmaceuticals Inc.This initial public offering of 5,000,000 ordinary shares was announced by the Universe Securities, LLC on March 23, 2021, at a public price of US$5.00 per ordinary share of the UPC stock.

    This IPO resulted in US$25 million in the aggregate gross proceeds without deducting the offering-related expenses and the underwriting discounts. Furthermore, the underwriter has been granted a 45-day option to buy additional 750,000 shares of UPC stock under this public offering. The trading of ordinary shares of UPC stock began on  March 23, 2021.

    UPC stock Future Plans

    Universe stock is planning to make use of these proceeds in various of its operational areas as well as for the growth in its manufacturing facilities. This revenue will help the UPC stock for the advancement in its research and development fields and will support the brand awareness, marketing, and advertisement of the Universe Stock. Some part of this amount will be used for UPC’s working capital and general corporate purposes.

    About Universe Pharmaceuticals Inc

    Universe Pharmaceuticals INC(UPC), a subsidiary of Sununion Holding Group Limited, is mainly working in the areas of research, development, marketing, and selling of traditional Chinese Medicine products in the Republic of China. Main focus of the UPC is the treatment of chronic diseases in the elders.UPC was founded in 2019 and its headquarter are located in Jiangxi, China.

    Conclusion:

    UPC stock is enjoying the bullish sentiment in the stock market despite the absence of any specific news by the Universe stock.UPC management is well aware of the future goals related to its development and expansion. Hence it is better for investors eyeing UPC stock to perform both technical and fundamental analysis before taking any decision.

  • China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    Shares of China SXT Pharmaceuticals, Inc. (SXTC) stock remained high in Monday’s pre-market trading session. SXTC stock was up by 33.33% to reach $2.44 a share at the time of this writing. It seems that SXTC stock was performing well in the previous trading session as it was up by 3.39% at the previous closing. But what made the stock high? Let’s deep dive to understand this bull.

    What’s happening?

    Sometimes nothing is good for everything and the same is the situation for SXTC stock. There is no particular activity by the China SXT stock, no press release today, no analysts’upgrades, or upswing targeted per share price of SXTC stock to support the rising stock price of China SXT. However it seems that sympathy play might be the driving force behind this bull as China Pharma Holdings, Inc has skyrocketed over 200% in pre-market session today in response to its fiscal year 2020 results.

    Recent Development

    Back on February 19, China SXT announced the approval of a 1 for 4 reverse split of its ordinary shares by its board of directors. These split-adjusted ordinary shares of SXTC began to trade on February 22, 2021. In connection with this announcement, shareholders of China SXT stock received one new share for every four shares which they owned. As of February 18, China SXT had approximately 62,057,584 outstanding ordinary shares which reduced to 15,514,396 approximately after the reverse split.

    Here is what you need to know about China SXT Pharmaceuticals, Inc.

    • China SXT is mainly operating in the fields of research, development, manufacturing, and marketing of its traditional Chine medicine piece tablets in the Republic of China. SXTC stock has a current market cap of 28.391M.
    • China SXT is a well-established company that provided services to 116 pharmaceutical companies, served 56 pharmacies and 76 hospitals as of May 2020.
    • Feng Zhou, a graduate of Pla National Defense University, is the Chief Executive Officer of the SXTC.
    • China SXT Pharmaceuticals was founded in 2005 and its headquarters are in Taizhou, China.

    Conclusion

    Things are going in favor of SXTC stock as far as market sentiment is concerned but no one knows how long this trend will continue in the future. There is no update about the earnings report so far by the China SXT. In a nutshell, investors should keep an eye on this stock.

  • Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Shares of Immutep Limited (IMMP) stock were high in Thursday’s intraday trading after facing the downtrend of 5.73% at the last trade. IMMP stock price saw a surge of 43.33% today to reach $3.76 a share as of this writing.We find no particular activity by the IMMP stock to support this rise. Let’s deep dive to explore more of it.

    What’s happening?

    Immutep Limited (IMMP) is a biotechnology company focused on the research and development of immunotherapeutic products to treat cancer and autoimmune diseases. The rising stock price of IMMP has nothing to do with any specific announcement or press release by Immutep. However some investors believe that this gain is mainly due to the recent positive announcement by the Bristol Myers Squibb related to Phase 2/3 RELATIVITY-047, a trial related to Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab)

    Recent Announcements by IMMP stock.

    On March 16, 2021, IMMP announced the second trial and collaboration agreement with Merck & Co Inc in order to test its lead product for the treatment of the Second Head & Neck Cancer Study.According to this agreement, IMMP will perform a clinical trial called TACTI-003with160 patients of the 1st line head and neck squamous cell carcinoma (HNSCC).IMMP will observe the results by evaluating the efficacy and safety of its lead product eftilagimod alpha along with pembrolizumab, a Merck’s product.

    On March 09, 2021,Immutep secured the second United States patent grant for Eftilagimod Alpha and PD-1 pathway inhibitor which was filed as a  divisional application followed by the parent patent announced on December 30, 2020.This patent will expire on 20 January 2036 and will help in the clinical development programs of the Immutep in the future.

    Conclusion:

    Things are going well for the penny IMMP stock as far as market sentiment is concerned but the gain without any major reason usually doesn’t last for a long time.Investors having long-term prospects usually don’t mind the short-term bulls and bears rather they focus more on the overall development and expansion of the business.

  • Molecular Data Inc. (MKD) stock gains in the Pre-Market: Things you need to know

    Shares of Molecular Data Inc. (MKD) were gaining in Thursday’s pre-market after following the downtrend in the previous open market. MKD stock price saw a jump of 4.81% to reach $1.10 a share at the time of this writing. MKD stock price dropped to $1.04 and down by 7.96% at the previous closing. Let’s try to find the reason behind this rise.

    What’s happening?

    Molecular Data Inc. (MKD) is the leading chemical e-commerce-based platform in the Republic of China. MKD’s rising stock price today captivated the attention of individuals who are looking for some reason. Still, the reality is somewhat different from expectations. We find no particular news by the company today, no earnings report, no analyst upgrades, or upswing targeted MKD stock price to explain the culprit behind this rise. However, Molecular Data did announce some of its recent development in the early days of this month.

    Recent Agreements

    On March 09, 2021, MKD stock signed the supply frame agreement with Anhui Gujing Distillery Co., Ltd for becoming the key supplier of the chemical and biological reagents and laboratory equipment and consumables to expandMKD’s presence in the food and beverage industry. Molecular Data will provide approximately 2 million stock-keeping units (SKUs) to Gujing for its domestic and foreign laboratory brands and suppliers. On the last day, MKD stock announced the MOU for the potential transaction and a stake in the famous brand name in the U.S to strengthen its presence in America.

    On March 05, 2021, Molecular Data entered into the cooperation agreement with Yili Industrial Group Co., pursuant to which the laboratory supplies Mall and centralized procurement platform of MKD would become branches and subsidiaries of Yili Group.

    Conclusion

    So far, so good for MKD stock price, but one should remember that rising stock price despite the absence of reason could not be the base for any decision about the particular stock.MKD stock has shown developments in recent times, and its business model suits the COVID world. In short, individuals eyeing MKD stock have to get the nitty-gritty details of it.

  • IMAC Holdings, Inc. (IMAC) stock is falling today. Things you need to know

    IMAC Holdings, Inc. (IMAC) is an orthopedic treatment provider in medical advancements and care regeneration centers in the U.S. IMAC stock saw a downtrend of 5.78% today to drop at $1.63 a share as of this writing. IMAC Holdings recently announced the pricing of the public offering of its common stock. Let’s deep dive to explore more of it.

    What’s happening?

    IMAC has announced a public offering price of $1.60 per share for 10,625,000 shares of its common stock for gross proceeds of $17.0 million. The net proceeds are estimated to be approximately $16.0 million after deducting underwriting discounts. The IMAC holdings along with its co-founder and chief operating officer have the grant of 45-day option to buy up to 15% shares of its common stock under this offering. The offering will close probably on March 26, 2021.

    IMAC stock is planning to use the net proceeds to meet the expenses related to the acquisition of medical clinics and in the launching of its healthcare clinics, to finance outstanding promissory notes, to meet expenses related to the development of new potential treatments in the future, and for general corporate purposes.

    A Financial look at IMAC stock

    In the first week of March 2021, IMAC stock reported its 2020 financial results in which IMAC recorded total net patient revenue of $12.8 million in the fourth quarter which was 15% less than the $15.1 million of prior year.Net loss was decreased to $5.0 million or $0.45 per share of IMAC as compared to a net loss of $6.5 million or $0.84 per share of IMAC in the same quarter of the previous year.IMAC Holdings had $2.6 million cash at the end of the fourth quarter while it was $0.4 million in 2019.

    Conclusion:

    The penny IMAC stock is still gloomy today in the stock market. Companies like Pfizer and Johnson & Johnson have greatly attracted investors due to the development of the COVID-19 vaccine and the companies working on other ailments have suffered to some extent. In a nutshell, individuals eyeing IMAC stock have to research its balance sheet, fundamentals, and growth prospects before taking any step.